南通市全球基金耐多药结核病项目患者治疗情况分析

发布时间：2018-08-29 16:29

【摘要】：目的 :分析南通市第7轮中国全球基金结核病项目患者治疗情况,为今后耐多药肺结核患者的管理与治疗提供参考依据。方法:通过中国疾病预防控制信息系统结核病管理信息子系统,分析2009年10月1日~2014年6月30日南通市确诊的耐多药肺结核患者纳入治疗及治疗转归情况。结果:共确诊234例耐多药肺结核患者,174例纳入项目进行标准化方案治疗,纳入率74.4%。144例达到24个月疗程的耐多药肺结核治疗患者中,90例完成治疗疗程,占62.5%。完成24个月标准化方案治疗且在疗程后12个月进行至少5次痰结核分枝杆菌培养共78例,治愈率71.8%;30岁年龄组治愈率最高为80.0%,30~59岁年龄组治愈率最低为33.3%;不同登记分类中,初治失败治愈率最高为100.0%,复治失败治愈率最低为57.1%。不同性别、年龄组和不同登记类别的治愈率差异无统计学意义(P0.05)。结论:耐多药肺结核疗程长,治愈率低,费用高,政府应加大对耐多药结核病防治经费的投入,提高患者治疗依从性。同时遵循早期规律、全程、联合、适量用药,规范治愈结核病,减少耐药结核病的发生。在确保有高质量的抗结核药物的不间断供应的同时,尽早对患者进行标准化或个性化治疗,提高耐多药肺结核治愈率。
[Abstract]:Objective: to analyze the treatment situation of the 7th round of China Global Fund TB Project in Nantong City, and to provide reference for the management and treatment of MDR-TB patients in the future. Methods: the tuberculosis management information subsystem of China disease prevention and control information system was used to analyze the treatment and outcome of MDR-TB patients diagnosed in Nantong City from October 1, 2009 to June 30, 2014. Results: a total of 234 cases of MDR-TB were diagnosed and 174 cases were included in the project for standardized treatment. The inclusion rate was 74.40.144 cases of MDR-TB patients who had reached the 24-month course of treatment completed the course of treatment, accounting for 62.5%. A total of 78 cases of Mycobacterium tuberculosis were treated with 24 months standardized regimen and 12 months after the treatment. The cure rate was 71.8%. The highest cure rate was 80.0% and the lowest was 33.3% in the 30- to 59-year-old group. The cure rate of initial failure was 100.0 and that of recurrent failure was 57.1. There was no significant difference in cure rate among different gender, age groups and different registration categories (P0.05). Conclusion: MDR-TB has a long course of treatment, low cure rate and high cost. The government should increase the expenditure on MDR-TB prevention and treatment, and improve the compliance of patients with MDR-TB. At the same time, follow the early law, the whole process, combined, appropriate drug use, standardized cure tuberculosis, reduce the occurrence of drug-resistant tuberculosis. While ensuring the continuous supply of high quality antituberculous drugs, standardized or individualized treatment should be carried out as soon as possible to improve the cure rate of multidrug resistant pulmonary tuberculosis (MDR-TB).
【作者单位】：南通市疾病预防控制中心;
【基金】：第7轮全球基金结核病项目(CHN-708-G11-T)
【分类号】：R52

【参考文献】